FUENTES CARO, EDUARDO ANDRES
Thumbnail Image
Preferred name
FUENTES CARO, EDUARDO ANDRES
Main Affiliation
Email
efuentes@udd.cl
ORCID
Scopus Author ID
57150478000

Research Output

2024 2024 0.0 0.0 0.2 0.2 0.4 0.4 0.6 0.6 0.8 0.8 1.0 1.0

Filters

1
1
Reset filters

Settings
Now showing 1 - 1 of 1
No Thumbnail Available
Publication

Quadruple therapies show a higher eradication rate compared to standard triple therapy for Helicobacter pylori infection within the LEGACy consortium. A multicenter observational study in European and Latin American countries

2024 , Patricio Medel‐Jara , Diego Reyes Placencia , Eduardo Fuentes‐López , Oscar Corsi , Gonzalo Latorre , Rosario Antón , Elena Jiménez , Ana Miralles‐Marco , Carmelo Caballero , Hugo Boggino , Daniel Cantero , Rita Barros , João Santos‐Antunes , Marc Díez , Luis A. Quiñones , Erick Riquelme , Antonio Rollán , Leslie C. Cerpa , Ivania Valdés , Olga P. Nyssen , Leticia Moreira , Javier P. Gisbert , M. Constanza Camargo , Nayeli Ortiz‐Olvera , Alberto M. Leon‐Takahashi , Erika Ruiz‐Garcia , Edith A. Fernández‐Figueroa , Marcelo Garrido , Gareth I. Owen , Andrés Cervantes , Tania Fleitas , Arnoldo Riquelme

AbstractIntroductionGastric cancer (GC) is one of the most lethal malignancies worldwide. Helicobacter pylori is the primary cause of GC; therefore, its eradication reduces the risk of developing this neoplasia. There is extensive evidence regarding quadruple therapy with relevance to the European population. However, in Latin America, data are scarce. Furthermore, there is limited information about the eradication rates achieved by antibiotic schemes in European and Latin American populations.ObjectiveTo compare the effectiveness of standard triple therapy (STT), quadruple concomitant therapy (QCT), and bismuth quadruple therapy (QBT) in six centers in Europe and Latin America.MethodsA retrospective study was carried out based on the LEGACy registry from 2017 to 2022. Data from adult patients recruited in Portugal, Spain, Chile, Mexico, and Paraguay with confirmed H. pylori infection who received eradication therapy and confirmatory tests at least 1 month apart were included. Treatment success by each scheme was compared using a mixed multilevel Poisson regression, adjusting for patient sex and age, together with country‐specific variables, including prevalence of H. pylori antibiotic resistance (clarithromycin, metronidazole, and amoxicillin), and CYP2C19 polymorphisms.Results772 patients were incorporated (64.64% females; mean age of 52.93 years). The total H. pylori eradication rates were 75.20% (255/339) with STT, 88.70% (159/178) with QCT, and 91.30% (191/209) with QBT. Both quadruple therapies (QCT‐QBT) showed significantly higher eradication rates compared with STT, with an adjusted incidence risk ratio (IRR) of 1.25 (p: <0.05); and 1.24 (p: <0.05), respectively. The antibiotic‐resistance prevalence by country, but not the prevalence of CYP2C19 polymorphism, showed a statistically significant impact on eradication success.ConclusionsBoth QCT and QBT are superior to STT for H. pylori eradication when adjusted for country‐specific antibiotic resistance and CYP2C19 polymorphism in a sample of individuals residing in five countries within two continents.

View